Temporal and spatial heterogeneity of programmed cell death 1-Ligand 1 expression in malignant mesothelioma

Trametinib plus 4-Methylumbelliferone Exhibits Antitumor Effects by ERK Blockade and CD44 Downregulation and Affects PD-1 and PD-L1 in Malignant Pleural Mesothelioma

(2017) Hiroyuki Cho et al.   Journal of Thoracic Oncology

Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases

(2017) Hironori Uruga et al.   Journal of Thoracic Oncology

Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer

(2016) A. S. Mansfield et al.   ANNALS OF ONCOLOGY

Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial

(2016) Gérard Zalcman et al.   LANCET

Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer

(2016) Jamaal A Rehman et al.   MODERN PATHOLOGY

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Intra-tumoral heterogeneity in the expression of programmed-death (PD) ligands in isogeneic primary and metastatic lung cancer: Implications for immunotherapy

(2016) David J. Pinato et al.   OncoImmunology

Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer

(2016) Joseph McLaughlin et al.   JAMA Oncology

Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies

(2015) M. Ilie et al.   ANNALS OF ONCOLOGY

Heterogeneity of Programmed Cell Death Ligand 1 Expression in Multifocal Lung Cancer

(2015) A. S. Mansfield et al.   CLINICAL CANCER RESEARCH

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma

(2015) M. Callea et al.   Cancer Immunology Research

Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM)

(2015) Susana Cedrés et al.   PLoS One

Extrapleural Pneumonectomy in the Treatment of Epithelioid Malignant Pleural Mesothelioma

(2014) David J. Sugarbaker et al.   ANNALS OF SURGERY

Extrapleural Pneumonectomy for Malignant Mesothelioma: An Italian Multicenter Retrospective Study

(2014) Lorenzo Spaggiari et al.   ANNALS OF THORACIC SURGERY

Does Surgery Improve Survival of Patients with Malignant Pleural Mesothelioma?: A Multicenter Retrospective Analysis of 1365 Consecutive Patients

(2014) Pietro Bovolato et al.   Journal of Thoracic Oncology

B7-H1 Expression in Malignant Pleural Mesothelioma is Associated with Sarcomatoid Histology and Poor Prognosis

(2014) Aaron Scott Mansfield et al.   Journal of Thoracic Oncology

Systematic review of response rates of sarcomatoid malignant pleural mesotheliomas in clinical trials

(2014) Aaron S. Mansfield et al.   LUNG CANCER

Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma

(2009) A. Scherpereel et al.   EUROPEAN RESPIRATORY JOURNAL

Circos: An information aesthetic for comparative genomics

(2009) M. Krzywinski et al.   GENOME RESEARCH

Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR–induced stop signal

(2009) Brian T Fife et al.   NATURE IMMUNOLOGY

Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients☆

(2008) Piero Borasio et al.   EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY